Why Most PRP for Knee Arthritis Falls Short: The Platelet Dose Problem
- 2 days ago
- 8 min read
By Dr. Jeffrey Peng, MD · Published May 3, 2026 · 7 min read
Watch the Full Video
The data on platelet-rich plasma (PRP) for knee osteoarthritis is now overwhelming. PRP outperforms cortisone, hyaluronic acid, and saline placebo across multiple meta-analyses, and it is widely considered the single best injection we have for addressing pain, improving function, and even slowing the progression of knee arthritis. But there is a catch most patients — and even most physicians — do not realize. A large fraction of the PRP being injected into knees today is not actually doing anything. The issue is not whether PRP works as a treatment. The issue is one variable in how PRP is prepared that almost nobody is asking about: platelet dose. Get it wrong, and a PRP injection performs no better than a saline placebo.
In my practice, I focus on orthobiologics and ultrasound-guided procedures, and PRP dosing is something I have been emphasizing with patients and colleagues for years. This article covers three things every patient should understand before getting a PRP injection: the strength of the evidence that PRP works for knee arthritis, why most PRP delivered in U.S. orthopedic clinics still falls below a therapeutic dose, and the variable most discussions still miss — the platelet recovery rate of the PRP kit itself.
Does PRP Actually Work for Knee Arthritis?
A 2026 systematic review and meta-analysis published in International Orthopaedics pooled 62 randomized controlled trials and nearly 5,000 patients comparing PRP head-to-head against hyaluronic acid (HA), corticosteroid, and saline placebo for knee osteoarthritis. PRP improved both pain (VAS) and function (WOMAC) versus all three comparators at six months and maintained that advantage versus HA and corticosteroid out to twelve months in longer-term trials.
In other words, the question is no longer whether PRP works for knee arthritis. The evidence base is large, consistent, and increasingly mature. PRP addresses pain, restores function, and there is growing evidence it also slows the structural progression of osteoarthritis. The harder question — and the one that determines whether any individual patient actually benefits — is whether the PRP they are receiving has been prepared at a therapeutic dose.
Why Did the RESTORE Trial Show PRP Was No Better Than Placebo?
The RESTORE trial, published in JAMA in 2021, was a well-designed randomized placebo-controlled study that found PRP was no different from saline injection for symptoms or cartilage volume at twelve months in mild-to-moderate knee osteoarthritis. Headlines at the time framed this as proof that PRP does not work.
But when you look at how the PRP was actually prepared, a different picture emerges. The trial used a low-volume blood draw and a leukocyte-poor commercial system that produced a very low-dose PRP product — far below what newer dose-response data suggest is required to see a clinical effect. RESTORE did not show that PRP does not work. It showed that underdosed PRP does not work, which is exactly what we would predict for any therapy with a dose-response curve.
What Is the Therapeutic Threshold for PRP in the Knee?
A randomized trial by Bansal and colleagues published in Scientific Reports gave the field an actual number to target. They demonstrated that delivering an absolute count of approximately 10 billion platelets per knee injection was the threshold for clinically meaningful and sustained benefit at one year. Below that threshold, results faded. Above it, patients saw durable improvements in pain, function, and walking distance.
Equally important, the PRP group in that study showed a significant decline in intra-articular inflammatory mediators — interleukin-6 and TNF-alpha — at one month compared to the hyaluronic acid group. That matters, because intra-articular inflammation is one of the proposed mechanisms by which PRP slows the progression of osteoarthritis. Reaching the 10-billion-platelet threshold is not just about better pain relief; it appears to be the dose at which PRP begins meaningfully modifying the disease process inside the joint.
How Much Blood Should Be Drawn for a Knee PRP Injection?
For years, many providers were drawing 10 to 20 cc of blood, spinning it down, and calling that PRP. That volume simply does not deliver a therapeutic platelet dose for a large joint like the knee. And we no longer have to guess about this — the 2026 meta-analysis ran a subgroup analysis specifically on blood draw volume in PRP versus HA trials.
The result was striking. Low-volume PRP — under 40 cc of blood drawn — performed no better than hyaluronic acid. Higher-volume PRP — 40 cc and above — was significantly superior to HA on both six-month WOMAC and twelve-month VAS pain scores. Two patients can receive injections labeled as PRP and have very different outcomes for one reason: how much blood was drawn at the start.
The authors concluded that when actual platelet dose is not reported in a study — and unfortunately most PRP studies still do not report it — total blood draw volume is a useful proxy for whether a therapeutic dose was delivered. In clinical practice, 60 cc has become the working floor for a knee PRP injection because that is the volume needed to approach 10 billion platelets. Many physicians, including myself, are pushing higher. PRP has a clear dose-response curve; we do not yet know exactly where the ceiling is, but the data continue to suggest more is better. For older patients and those with more advanced arthritis, I increasingly use 120 cc draws targeting roughly 20 billion platelets.
Why Two PRP Kits Drawing the Same Blood Volume Can Deliver Different Doses
Blood draw volume has finally entered the PRP conversation. But this is where most discussions stop, and where the real problem hides. Because PRP has exploded over the last several years, there are now dozens of different commercial PRP kits on the market — and they are not created equal. Two 60 cc kits from two different manufacturers can deliver very different platelet doses to the joint. The kit matters as much as the blood draw.
Consider the most striking comparison I know of. The Arthrex Angel system advertises that it can process 180 cc of blood — three times the volume of most PRP kits. You would reasonably assume it delivers three times the platelets. In a randomized controlled trial using the Angel system, the final PRP product contained roughly 13 to 14 billion platelets per dose, which is well above the 10 billion threshold.
Now compare that to the Emcyte system. Emcyte processes 60 cc of blood — one-third the volume of the Angel — and in a randomized trial using the Emcyte system, the final PRP product still landed in a therapeutic range at roughly 8.5 billion platelets per dose. To compare these systems on equal footing, the 120 cc Emcyte kit lands at a similar price point as the Angel system. Doubling the platelet output puts the 120 cc Emcyte kit closer to 17 billion platelets in a single injection — significantly more platelets than the Angel system, with a smaller blood draw, at the same cost.
How is that possible? The answer is platelet recovery — the percentage of platelets in the original blood draw that actually make it into the final PRP product. The original Arthrex Angel system has a published platelet recovery of roughly 43%, meaning more than half of the platelets in a 180 cc draw are lost during processing. Newer Arthrex hardware reportedly improves this toward 60%. The current Emcyte system has a platelet recovery of approximately 90 to 95%. Run a 120 cc Emcyte draw at that recovery rate, and you are delivering close to 20 billion platelets in a single injection.
This is not just theoretical for me. In my own practice, I have had well over a hundred patients try a 60 cc PRP injection and then return for a 120 cc injection. Almost without exception, they prefer the higher dose — better pain relief, better functional improvement, and based on what we already know about dose-response, hopefully a better job of slowing the underlying disease. I cannot show you a randomized trial that proves this, but the pattern has been consistent enough across patients that it has changed how I dose every PRP I do.
What Should Patients Ask Their Provider Before a PRP Injection?
If you are considering PRP for knee arthritis, two specific questions will tell you most of what you need to know about whether your injection is likely to work.
First: How much blood are you drawing? For a knee, anything under 40 cc has no high-quality evidence supporting clinical superiority over HA. For most patients, 60 cc should be the floor. For older patients and more advanced arthritis, 120 cc is reasonable.
Second: What is the platelet recovery rate of the system you are using? If your provider does not know the answer, that is a meaningful red flag. Anything below 80% is leaving therapeutic platelets behind. A high-recovery system at 90% or more is doing significantly more with the same blood draw.
If you are a clinician reading this: it is worth taking a hard look at the platelet recovery data for whatever kit you are using. Patients deserve to know how many platelets actually end up in their joint, not just how many came out of their arm.
The Bottom Line on PRP Dosing for Knee Arthritis
PRP is the single best injection we currently have for knee osteoarthritis. The evidence on that point is no longer in serious dispute. But the same body of evidence makes clear that not all PRP is the same. The combination of an adequate blood draw — generally 60 cc or more for the knee — and a kit with high platelet recovery is what determines whether a patient actually receives a therapeutic dose.
If you are weighing PRP for knee arthritis and want a clear, individualized assessment of whether it is the right next step in your care, you can schedule a consultation in my Campbell, California clinic. You can also read more about how I approach PRP and the dosing protocols I use on the PRP service page.
References
1. Centeno CJ, Berger DR, Pelle AJ, Dodson E, Hernigou P, Murphy MB. Autologous platelet-rich plasma versus hyaluronic acid, corticosteroids or saline for knee osteoarthritis: can blood draw volume serve as a proxy for platelet dose? A systematic review and meta-analysis. International Orthopaedics. 2026. doi:10.1007/s00264-026-06782-7
2. Bennell KL, Paterson KL, Metcalf BR, et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA. 2021;326(20):2021-2030. doi:10.1001/jama.2021.19415
3. Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: correct dose critical for long term clinical efficacy. Scientific Reports. 2021;11(1):3971. doi:10.1038/s41598-021-83025-2
4. Baria M, Pedroza A, Kaeding C, et al. Platelet-rich plasma versus microfragmented adipose tissue for knee osteoarthritis: a randomized controlled trial. Orthopaedic Journal of Sports Medicine. 2022;10(9):23259671221120678. doi:10.1177/23259671221120678
5. Anz AW, Hubbard R, Rendos NK, Everts PA, Andrews JR, Hackel JG. Bone marrow aspirate concentrate is equivalent to platelet-rich plasma for the treatment of knee osteoarthritis at 1 year: a prospective, randomized trial. Orthopaedic Journal of Sports Medicine. 2020;8(2):2325967119900958. doi:10.1177/2325967119900958
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
